Patents by Inventor Mark K. Bennett

Mark K. Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7604951
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 20, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Patent number: 7598050
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 6, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20090215093
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.
    Type: Application
    Filed: May 1, 2009
    Publication date: August 27, 2009
    Applicant: Proteolix, Inc.
    Inventors: Mark K. Bennett, Tonia J. Buchholz, Susan D. Demo, Guy J. Laidig, Evan R. Lewis, Mark S. Smyth
  • Patent number: 7563585
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: July 21, 2009
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20080261819
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Application
    Filed: May 12, 2008
    Publication date: October 23, 2008
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7425418
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a retinoid X receptor as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: September 16, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Todd M. Kinsella, Esteban Masuda, Mark K. Bennett, Justin E. Warner, David C. Anderson
  • Patent number: 7422867
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: September 9, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7378248
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd R. Pray, Todd M. Kinsella, Mark K. Bennett
  • Patent number: 7378251
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 27, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7374894
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL 4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a chloride intracellular channel 1 (CLIC1) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vivo and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: May 20, 2008
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20080108066
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: April 4, 2007
    Publication date: May 8, 2008
    Inventors: Esteban Maduda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7252952
    Abstract: The present invention relates to methods and compositions utilizing inteins to generate libraries of cyclic peptides in vivo. The prevent invention also relates to methods for inhibiting protein-protein interaction.
    Type: Grant
    Filed: April 23, 2003
    Date of Patent: August 7, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: James B. Lorens, Todd M. Kinsella, Todd Pray, Mark K. Bennett
  • Patent number: 7241581
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: July 10, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7208289
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: December 30, 2004
    Date of Patent: April 24, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7189523
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a BAP-37 as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: March 13, 2007
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7141434
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize an adenosine kinase as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: November 28, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Patent number: 7071190
    Abstract: The invention relates to the inhibition of tubulin polymerization. The invention provides compounds and methods for inhibiting tubulin polymerization. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: February 18, 2003
    Date of Patent: July 4, 2006
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Mark K. Bennett, Susan Demo
  • Patent number: 6979549
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a CLLD8 protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Grant
    Filed: July 16, 2002
    Date of Patent: December 27, 2005
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20040033538
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a c-Myc protein as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: August 16, 2002
    Publication date: February 19, 2004
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson
  • Publication number: 20040014149
    Abstract: The present provides compounds capable of modulating IL-4 receptor-mediated IgE production, as well as IL-4 induced processes associated therewith, methods and kits for identifying such compounds that utilize a thioredoxin-like 32 kDa protein (TXNL) as a surrogate analyte and methods of using the compounds in a variety of in vitro, in vitro and ex vivo contexts.
    Type: Application
    Filed: July 16, 2002
    Publication date: January 22, 2004
    Inventors: Esteban Masuda, Todd M. Kinsella, Justin E. Warner, Taisei Kinoshita, Mark K. Bennett, David C. Anderson